ClinicalTrials.gg
Not yet recruitingNCT06254092Updated Feb 12, 2024

Effect of Tourniquet Binding of Cervical on the Blood Volume of Amniotic Fluid in Cesarean Section

An interventional study of tourniquet binding of cervical in Amniotic Fluid Embolism and Pulmonary Hypertension, sponsored by First People's Hospital of Chenzhou. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by First People's Hospital of Chenzhou · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
43rd of 47
28 · median 100
Started
2024
with 6 others
No phase
12 of 85
7 open now
Primary completion
2024-07
later than 3 of 35 live
Registered
60th of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 43rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 35 other live ones, and was the 60th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 20 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

This study was conducted to investigate whether the use of tourniquet after delivery of the fetus could reduce the amount of amniotic fluid entering the bloodstream and thus reduce the incidence of intraoperative adverse events.

Read the detailed description

Amniotic fluid embolism (AFE) is a rare complication specially to obstetrics.When amniotic fluid enters the maternal circulation , a sudden onset of a series of pathophysiologic changes such as pulmonary hypertension, hypoxemia, circulatory failure, disseminated intravascular coagulation, and multiorgan failure may occur. Routinely, the typical AFE triad is uneasy to discover, and nonspecific adverse reactions such as irritability, chills, chest tightness and shortness of breath, transient drop in blood pressure, and nausea and vomiting are often seen during delivery of the fetus and placenta. All of the above symptoms may suggest that the amniotic fluid has entered into the bloodstream. In clinical anesthesia, investigators observed that women with placenta praevia and placenta implantation were less likely to suffer these nonspecific symptoms after delivery of the fetus compared with women with normal pregnancies.The investigators speculated it might be related to the fact that obstetricians used tourniquets to reduce intraoperative hemorrhage in the former, blocking venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus. Therefore, this study was conducted to investigate whether the use of tourniquet after delivery of the fetus could reduce the amount of amniotic fluid entering the bloodstream and thus reduce the incidence of intraoperative adverse events.

03

Conditions studied

  • Amniotic Fluid Embolism
  • Pulmonary Hypertension

Keywords

  • amniotic fluid entering the bloodstream
  • blood volume of amniotic fluid
  • Amniotic fluid embolism
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Single pregnancy
  2. Be in good health, with no high blood pressure or heart disease during pregnancy
  3. Without placenta previa and placenta implantation
  4. No abdominal adhesions, suitable for operation
  5. Signed by the pregnant woman and her family

Exclusion criteria

Exclusion criteria

  1. Serious coagulation abnormality
  2. Preoperative severe cardiac, cerebral, pulmonary, hepatic, renal and other important organs insufficiency and electrolyte abnormality combined with placenta praevia or placenta implantation
  3. Multiple pregnancies
  4. Previous history of abdominal surgery
  5. Intraoperative drug allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    tourniquet

    The investigators use tourniquets to bind the cervical for intervention groups to block venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus.

    Procedure: tourniquet binding of cervical

Interventions

  • Proceduretourniquet binding of cervical

    The procedure will be performed by surgeons with rich experience in clinical work

06

What researchers measure

Primary outcomes

  1. sTn

    sTn refers to meconium and mucin extracted from amniotic fluid. The presence of sTn in the patient's serum is a diagnostic method that can directly prove that mucin derived from amniotic fluid has entered the maternal circulation.

    Time frame: before the fetus is delivered,after the fetus is delivered,before the puerpera is sent back to the ward

Secondary outcomes

  1. HR MAP

    Measurement of HR by patient monitor and MAP by placing an arterial puncture catheterization.

    Time frame: before the fetus is delivered,after the fetus is delivered,before the placenta is delivered,after the placenta is delivered,after releasing the tourniquet,before the puerpera is sent back to the ward

  2. SPO2,PaO2,PaCO2

    the respiratory parameters in arterial blood gas

    Time frame: before the fetus is delivered,after the fetus is delivered,before the placenta is delivered,after the placenta is delivered,after releasing the tourniquet,before the puerpera is sent back to the ward

  3. Thrombelastogram(TEG)

    Thrombelastography (TEG) is an indicator of the dynamic changes of blood coagulation. It can evaluate thrombelastography and compensate for the failure of routine examinations to reflect the fibrinolytic system and platelet function.

    Time frame: before the fetus is delivered,before the puerpera is sent back to the ward

  4. Adverse events

    Irritability, chills, chest tightness and shortness of breath, transient drop in blood pressure, and nausea and vomiting

    Time frame: perioperatively

  5. Hemorrhage

    The using of tourniquets can reduce intraoperative hemorrhage. The postpartum hemorrhage reflects the coagulation function of patients.

    Time frame: before the puerpera is sent back to the ward, 2 hours after the puerpera back to ward

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jul 2024, 5 months later.

Of 135 non-industry interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's planned 5 months is below that.

Counting every sponsor, half of 150 studies reached it within 23 months; a quarter within 9 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 12, 2024
StartEst.
Jan 31, 2024
Primary completionEst.
Jul 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254092
Lead sponsor
First People's Hospital of Chenzhou
Responsible party
zhiming zhang (chief, First People's Hospital of Chenzhou) — Principal investigator
First posted
Feb 12, 2024
Start date
Jan 31, 2024 (estimated)
Primary completion
Jul 1, 2024 (estimated)
Completion
Aug 1, 2024 (estimated)
Last update
Feb 12, 2024

Study contacts

Yingying Zhou
Contact
zyy172250133@163.com
+861861202387
Yao Chen
Contact
chenyao0810@163.com
+8615115563778
Zhiming zhang
principal investigator · Chenzhou NO. 1 people's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion